Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843399 · ClinicalTrials.gov registry record
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 15,498
- Enrollment target
NCT02843399 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 15,498 participants.
The verdict
NCT02843399 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 15,498 participants
- Enrollment target
Study Summary
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,498 participants |
| Start Date | 2016-08-15 |
| Est. Completion | 2016-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843399
The ClinicalTrials.gov registry entry for NCT02843399 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15,498 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02843399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02843399 about?
NCT02843399 is a clinical study titled "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy". Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
What is the current status of trial NCT02843399?
This trial is currently completed. The enrollment target is 15,498 participants. The study started on 2016-08-15. Estimated completion is 2016-12-15.
Who is sponsoring clinical trial NCT02843399?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.